文献速递冠心病

非ST段抬高型急性冠脉综合征中替格瑞洛与普拉格雷的比较

Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

该研究为ISAR-REACT 5试验中不稳定心绞痛与非ST段抬高型心肌梗死预设亚组的析因分析,共纳入替格瑞洛组1179例和普拉格雷组1186例,计划行侵入性治疗。结果显示普拉格雷较替格瑞洛降低1年死亡、心肌梗死或卒中复合终点风险(HR 1.41;95%CI 1.04-1.90),且不增加BARC 3-5级出血风险。

要点

  • NSTE-ACS计划侵入治疗者,普拉格雷较替格瑞洛降低1年死亡、心梗或卒中复合终点。
  • 普拉格雷未增加BARC 3-5级出血风险(HR 1.09;95%CI 0.72-1.65)。
  • 析因分析性质,结论需进一步研究证实。

核心结论

  • 在NSTE-ACS患者中,普拉格雷较替格瑞洛降低1年死亡、心肌梗死或卒中复合风险,且不增加出血风险。

研究设计与样本

  • ISAR-REACT 5随机试验中不稳定心绞痛与非ST段抬高型心肌梗死预设亚组的析因分析,替格瑞洛组1179例、普拉格雷组1186例,计划行侵入性治疗。

主要发现

  • 主要终点在替格瑞洛组101例(8.7%)、普拉格雷组73例(6.3%),HR 1.41(95%CI 1.04-1.90)。
  • 全因死亡HR 1.43(95%CI 0.93-2.21),心肌梗死HR 1.43(95%CI 0.94-2.19)。
  • 安全终点(BARC 3-5级出血)替格瑞洛组49例(5.2%)、普拉格雷组41例(4.7%),HR 1.09(95%CI 0.72-1.65)。
  • 里程碑分析显示普拉格雷的疗效优势在第一个月后持续存在。

临床怎么用

  • 对NSTE-ACS计划侵入性治疗的患者,可考虑优先选用普拉格雷而非替格瑞洛以降低缺血事件风险。
  • 需结合析因分析证据级别谨慎解读,个体化决策。

局限性

  • 分析为析因性质,结果需进一步研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current guidelines recommend intensified platelet inhibition by prasugrel or ticagrelor in patients with unstable angina (UA) or non-ST-segment elevation (NSTE) myocardial infarction (MI). OBJECTIVES: This study sought to investigate the benefits and risks of ticagrelor as compared with prasugrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) and planned invasive management. METHODS: This post hoc analysis combines the pre-specified subgroups of UA and NSTEMI of the randomized ISAR-REACT 5 trial. It included 1,179 patients assigned to ticagrelor and 1,186 assigned to prasugrel. Ticagrelor was started immediately after randomization and prasugrel after coronary angiography. The primary endpoint was a composite of death, MI, or stroke during 1-year follow-up, and the safety endpoint was Bleeding Academic Research Consortium class 3-5. RESULTS: The primary endpoint was reached in 101 (8.7%) patients in the ticagrelor and in 73 (6.3%) patients in the prasugrel group (hazard ratio [HR]: 1.41; 95% confidence interval [CI]: 1.04 to 1.90). The HR for all-cause death was 1.43 (95% CI: 0.93 to 2.21) and that for MI 1.43 (95% CI: 0.94 to 2.19). The safety endpoint occurred in 49 (5.2%) patients in the ticagrelor and in 41 (4.7%) patients in the prasugrel group (HR: 1.09; 95% CI: 0.72 to 1.65). Landmark analysis revealed persistence of the efficacy advantage with prasugrel after the first month. CONCLUSIONS: In patients with NSTE-ACS, we found that prasugrel was superior to ticagrelor in reducing the combined 1-year risk of death, MI, and stroke without increasing the risk of bleeding. Due to the post hoc nature of the analysis, these findings need confirmation by further studies. (Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome; NCT01944800).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Valina C, Neumann FJ, Menichelli M, et al. Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2020. PMID: 33213722. doi:10.1016/j.jacc.2020.09.584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。